Immunome Inc.
IMNM | NASDAQ
$25.07
+$1.10 (+4.59%)
At close: Sep 21, 2026, 4:00 PM ET
$25.07
$0 (0.00%)
Pre-market:
Sep 22, 2026, 7:24 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 6.94M | 9.04M | 14.02M | n/a | n/a | n/a |
Cost of Revenue | 2.96M | n/a | n/a | n/a | n/a | 755K |
Gross Profit | 3.99M | 9.04M | 14.02M | n/a | n/a | -755K |
Operating Income | -214.11M | -305.8M | -109.53M | -36.9M | -25.2M | -12.26M |
Interest Income | 11.72M | 12.84M | 2.72M | 5K | 10K | 1K |
Pretax Income | -212.39M | -292.96M | -106.81M | -36.9M | -24.71M | -17.84M |
Net Income | -212.39M | -292.96M | -106.81M | -36.9M | -24.71M | -17.84M |
Selling & General & Admin | 43.77M | 32.96M | 19.66M | 13.63M | 11.09M | 4.78M |
Research & Development | 174.33M | 129.54M | 23.09M | 23.27M | 14.11M | 6.73M |
Other Expenses | n/a | 152.34M | 80.8M | n/a | n/a | n/a |
Operating Expenses | 218.1M | 314.84M | 123.55M | 36.9M | 25.2M | 11.51M |
Interest Expense | n/a | n/a | n/a | 5K | 10K | 38K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 221.05M | 314.84M | 123.55M | 36.9M | 25.2M | 12.26M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 87.35M | 58.64M | 19.84M | 12.13M | 11.54M | 10.11M |
Shares Outstanding (Diluted) | 87.35M | 58.64M | 19.84M | 12.13M | 11.54M | 10.11M |
EPS (Basic) | -2.43 | -5 | -5.38 | -3.09 | -2.14 | -1.69 |
EPS (Diluted) | -2.43 | -5 | -5.38 | -3.09 | -2.14 | -1.69 |
EBITDA | -209.44M | -151.35M | -28M | -36.26M | -23.95M | -17.04M |
EBIT | -212.39M | -153.46M | -28.73M | -36.89M | -24.7M | -17.8M |
Depreciation & Amortization | 2.96M | 2.1M | 728K | 631K | 755K | 755K |
Add to Watchlist
Select watchlists to add or remove IMNM